普生股份有限公司 Approved
最後更新時間 2025/07/10 , 06:24 PM
最後更新時間 2025/07/10 , 06:24 PM
負責人
Lin,Zong-Qing
統一編號
47299918
成立日期
1984/06/11
資本額
NT$800,000,000
實收資本額
NT$608,243,700
股票代號
4117
電話
03-5779221
地址
No. 6, Chuangsin 1st Rd., Shuangxi Vil., Baoshan Township, Hsinchu County, 308, Taiwan
董監事
姓名 職稱 持有股份 代表法人
Lin,Zong-Qing Chairman 13.19% DOLPHIN INTERNATIONAL CORPORATION
Chen,Bi-Hua Director 19.41% HONG KONG CHRISTINA INTERNATIONAL CO., LTD.
Lin,Meng-De Director 0.81%
Zhuang,Zhe-Ren Independent Director 0.00%
Wu,Jin-Lie Independent Director 0.00%
Lin,Qian-Ru Independent Director 0.00%
Guo,Xu-Song Independent Director 0.00%
營業項目
  • Manufacture of Medicinal Chemical Products(200599)
  • Manufacture of Drugs and Medicines(200211)
  • Manufacture of Cosmetics(193299)
  • 公司歷程
  • Change Capital to 800,000,000
    2019/08/27
  • 員工人數
    財務報表
    項目 2024 2023 2022
    Operating income 111,275 264,825 370,459
    Operating cost 97,711 202,119 198,606
    Profit (loss) of initial recognition of biological asset and agricultural products - - -
    Profit (loss) on changes in fair value less costs to sell of biological asset for current period - - -
    Operating gross profit (loss) 13,564 62,706 171,853
    Unrealized profit (loss) on sales of goods - - -
    Realized profit (loss) on sales of goods - - -
    Operating gross profit (loss), net 13,564 62,706 171,853
    Operating expenses 110,289 232,642 212,724
    Other gain (loss), net - - -
    Operating profit (loss) -96,725 -169,936 -40,871
    Non-operating income and expenses -9,237 -17,782 -5,256
    Net profit (loss) before tax -105,962 -187,718 -46,127
    Income tax expense (benefits) -146 12,129 7,690
    Net profit (loss) of ongoing business for the current period -105,816 -199,847 -53,817
    Profit (loss) of closed units - - -
    Profit (loss) of non-jointly controlled equity before merger - - -
    Net profit (loss) for the current period -105,816 -199,847 -53,817
    Other comprehensive profit (loss), net 8,893 3,428 12,227
    Comprehensive net profit and loss of non-jointly controlled equity before merger - - -
    Total comprehensive profit and loss for the current period -96,923 -196,419 -41,590
    Net profit (loss) attributable to owners of parent company -106,019 -198,834 -53,192
    Net profit (loss) form equity attributable to former owner of business combination under common control - - -
    Net profit (loss) attributable to non-controlling interests 203 -1,013 -625
    Comprehensive profit (loss) attributable to owners of parent company -97,122 -195,386 -40,993
    Comprehensive profit (loss) form equity attributable to former owner of business combination under common control - - -
    Comprehensive profit (loss) attributable to non-controlling interests 199 -1,033 -597
    Basic earnings per share (yuan) -1 -3 0
    項目 2024 2023 2022
    Net cash inflow (outflow) from operating activities -28,268 225,684 224,592
    Net cash inflows (outflows) from investing activities -1,255,535 -342,305 -277,909
    Net cash inflow (outflow) from financing activities 1,296,751 72,373 -9,736
    Effect of Exchange Rate Changes on Cash and Cash Equivalents -13,406 -812 16,463
    Increase (decrease) in cash and cash equivalents in the current period -458 -45,060 -46,590
    Beginning balance of cash and cash equivalents 217,123 262,183 308,773
    Ending balance of cash and cash equivalents 216,665 217,123 262,183
    項目 2024 2023 2022
    Current asset 416,615 401,852 550,973
    Non-current asset 2,743,336 2,135,481 999,599
    Total asset 3,159,951 2,537,333 1,550,572
    Current liability 407,523 1,029,297 98,038
    Non-current liability 2,350,004 1,011,389 759,468
    Total liability 2,757,527 2,040,686 857,506
    share capital 598,245 598,245 598,245
    Equity - secruity token - - -
    capital reserve 109,400 87,800 87,800
    retained earning -313,051 -207,032 -8,233
    Other equity 6,118 16,121 12,708
    Treasury stock - - -
    Total equity attributable to owners of parent company 400,712 495,134 690,520
    Equity attributable to former owner of business combination under common control - - -
    Equity attributable to non-controlling interest before business merger under common control - - -
    Non-controlling interests 1,712 1,513 2,546
    Total Equity 402,424 496,647 693,066
    Share capital awaiting retirement (unit: share) 0 0 0
    Issued shares of advance equity (unit: shares) 0 0 0
    Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) 0 0 0
    Net asset value per share 6 8 11
    動產抵押
    下載完整報告查看完整數據
    案件類別 債務人名稱 債務人統編 契約啟始日期 契約終止日期 抵押權人名稱 抵押權人統編 擔保債權金額
    選舉收入(政治獻金)
    收入名稱 收入金額
    總收入金額
    選舉支出(政治獻金)
    支出名稱 支出金額
    總支出金額
    標案拒往
    機關名稱 生效日期 截止日期
    進出口資料
    下載完整報告查看完整數據
    年份 月份 總進口實績(美金) 總出口實績(美金)
    商標
  • RealQuant
  • 竹創
  • GBC General Biologicals Corporation
  • GBC
  • 普生
  • P113
  • Mr.&Mrs.O
  • Kalistor 凱莉絲朵
  • GB
  • BIOFIBROSCORe
  • 專利
    政府標案
    標案名稱 機關名稱 決標日期 決標金額 是否得標
    裁判書查詢
  • Pay for the project
    2006
  • Compensation for damage
    2018
  • Others
    1998, 2024
  • Pay price
    2023, 2024
  • Enforcement
    2024
  • Payment order
    2023, 2024
  • Pay remuneration
    2023, 2024
  • Pay off loan, etc.
    2024
  • Compensation for damage
    2023
  • Pharmaceutical Affairs Law
    2020
  • Labor disputes grant enforcement
    2024
  • Petition for ruling to allow enforcement
    2024
  • 勞權違規
    日期 違反法規法條 罰鍰金額
    污染源裁處
    污染類別 裁處時間 裁處機關 裁處金額 違反事實 違反法令 裁處書字號 裁處理由及法令 公司地址
    本頁內所載之資料,所載資料之完整性、即時性和正確性仍應以資料來源單位為準。
    公司一有新動態,我們馬上通知你,追蹤公司讓你不錯過任何更新。